menu search

Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases

Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases
– Consistent and compelling clinical data across rare hematological diseases support five ongoing pivotal trials in thalassemia, sickle cell disease and pediatric pyruvate kinase (PK) deficiency – – Driving toward two additional PYRUKYND® indications, with potential FDA approvals in thalassemia in 2025 and sickle cell disease in 2026 – – Strong cash position expected to […] The post Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Di... Read More
Posted: Jan 9 2023, 01:00
Author Name: forextv
Views: 101992

Search within

Pages Search Results: